How to manage asparaginase hypersensitivity in acute lymphoblastic leukemia

Future Oncology

Volumn 10, Issue 16, 2014, Pages 2615-2627

  Burke, Michael J ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

acute lymphoblastic leukemia; asparaginase; asparaginase Erwinia chrysanthemi; hypersensitivity; silent inactivation; therapeutic drug monitoring

Indexed keywords

ASPARAGINASE; ASPARAGINASE MACROGOL; CORTICOSTEROID; DIPHENHYDRAMINE; PARACETAMOL; STEROID;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLERGIC REACTION; ANTIBODY RESPONSE; CHILDHOOD DISEASE; CLINICAL FEATURE; CLINICAL HYPERSENSITIVITY; DESENSITIZATION; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG MONITORING; DRUG SUBSTITUTION; ESCHERICHIA COLI; HIGH RISK PATIENT; HUMAN; IMMUNE RESPONSE; PECTOBACTERIUM CHRYSANTHEMI; PROPHYLAXIS; REVIEW; RISK FACTOR; SUBCLINICAL HYPERSENSITIVITY;

EID: 84919791996     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.14.138     Document Type: Review

References (66)

1. American Cancer Society. Cancer Facts and Figures 2014 (2014). www.cancer.orgf
2. Pui CH, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet 371(9617), 1030-1043 (2008).
3. Hunger SP, Loh ML, Whitlock JA et al. Children's Oncology Group's 2013 blueprint for research: Acute lymphoblastic leukemia. Pediatr. Blood Cancer 60(6), 957-963 (2013).
4. Broome JD. Evidence that the L-Asparaginase activity of guinea pig serum is responsible for its antilymphoma effects. Nature 191, 1114-1115 (1961).
5. Pieters R, Hunger SP, Boos J et al. L-Asparaginase treatment in acute lymphoblastic leukemia: A focus on Erwinia asparaginase. Cancer 117(2), 238-249 (2011).
6. Silverman LB, Gelber RD, Dalton VK et al. Improved outcome for children with acute lymphoblastic leukemia: Results of Dana-Farber Consortium Protocol 91-01. Blood 97(5), 1211-1218 (2001).
7. Woo MH, Hak LJ, Storm MC et al. Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia. J. Clin. Oncol. 18(7), 1525-1532 (2000).
8. Vrooman LM, Stevenson KE, Supko JG et al. Postinduction dexamethasone and individualized dosing of Escherichia coli L-Asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: Results from a randomized study-Dana-Farber Cancer Institute ALL Consortium Protocol 00-01. J. Clin. Oncol. 31(9), 1202-1210 (2013).
9. Larson RA, Fretzin MH, Dodge RK, Schiffer CA. Hypersensitivity reactions to L-Asparaginase do not impact on the remission duration of adults with acute lymphoblastic leukemia. Leukemia 12(5), 660-665 (1998).
10. Graham ML. Pegaspargase: A review of clinical studies. Adv. Drug Deliv. Rev. 55(10), 1293-1302 (2003).
11. Keding RE Discontinuation of Elspar (asparaginase for injection) 10,000 IU (2012). www.fda.gov
12. Akbayram S, Dogan M, Akgun C, Caksen H, Oner AF. A desensitization protocol in children with L-Asparaginase hypersensitivity. J. Pediatr. Hematol. Oncol. 32(5), e187-191 (2010).
13. Salzer WL, Asselin B, Supko JG et al. Erwinia asparaginase achieves therapeutic activity after PEGaspargase allergy: A report from the Children's Oncology Group. Blood 122(4), 507-514 (2013).
14. Zalewska-Szewczyk B, Gach A, Wyka K, Bodalski J, Mlynarski W. The cross-reactivity of anti-Asparaginase antibodies against different L-Asparaginase preparations. Clin. Exp. Med. 9(2), 113-116 (2009).
15. Muller HJ, Boos J. Use of L-Asparaginase in childhood ALL. Crit. Rev. Oncol. Hematol. 28(2), 97-113 (1998).
16. Avramis VI, Avramis EV, Hunter W, Long MC. Immunogenicity of native or pegylated E. coli and Erwinia asparaginases assessed by ELISA and surface plasmon resonance (SPR-biacore) assays of IgG antibodies (Ab) in sera from patients with acute lymphoblastic leukemia (ALL). Anticancer Res. 29(1), 299-302 (2009).
17. Shinnick SE, Browning ML, Koontz SE. Managing hypersensitivity to asparaginase in pediatrics, adolescents, and young adults. J. Pediatr. Oncol. Nurs. 30(2), 63-77 (2013).
18. Plourde PV, Jeha S, Hijiya N et al. Safety profile of asparaginase Erwinia chrysanthemi in a large compassionate-use trial. Pediatr. Blood Cancer 61(7), 1232-1238 (2014).
19. Raetz EA, Salzer WL. Tolerability and efficacy of L-Asparaginase therapy in pediatric patients with acute lymphoblastic leukemia. J. Pediatr. Hematol. Oncol. 32(7), 554-563 (2010).
20. Liu C, Kawedia JD, Cheng C et al. Clinical utility and implications of asparaginase antibodies in acute lymphoblastic leukemia. Leukemia 26(11), 2303-2309 (2012).
21. Panosyan EH, Seibel NL, Martin-Aragon S et al. Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia: Children's Cancer Group Study CCG-1961. J. Pediatr. Hematol. Oncol. 26(4), 217-226 (2004).
22. Zalewska-Szewczyk B, Andrzejewski W, Mlynarski W, Jedrychowska-Danska K, Witas H, Bodalski J. The anti-Asparagines antibodies correlate with L-Asparagines activity and may affect clinical outcome of childhood acute lymphoblastic leukemia. Leuk. Lymphoma 48(5), 931-936 (2007).
23. Muller HJ, Beier R, Loning L et al. Pharmacokinetics of native Escherichia coli asparaginase (Asparaginase medac) and hypersensitivity reactions in ALL-BFM 95 reinduction treatment. Br. J. Haematol. 114(4), 794-799 (2001).
24. Asselin BL, Whitin JC, Coppola DJ, Rupp IP, Sallan SE, Cohen HJ. Comparative pharmacokinetic studies of three asparaginase preparations. J. Clin. Oncol. 11(9), 1780-1786 (1993).
25. Avramis VI, Sencer S, Periclou AP et al. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: A Children's Cancer Group study. Blood 99(6), 1986-1994 (2002).
26. Willer A, Gerss J, Konig T et al. Anti-Escherichia coli asparaginase antibody levels determine the activity of second-line treatment with pegylated E. coli asparaginase: A retrospective analysis within the ALL-BFM trials. Blood 118(22), 5774-5782 (2011).
27. Vrooman LM, Supko JG, Neuberg DS et al. Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia. Pediatr. Blood Cancer 54(2), 199-205 (2010).
28. Asselin BL. The three asparaginases. Comparative pharmacology and optimal use in childhood leukemia. Adv. Exp. Med. Biol. 457, 621-629 (1999).
29. Tong WH, Pieters R, Kaspers GJ et al. A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia. Blood 123(3), 2026-2033 (2014).
30. Kurtzberg J, Asselin B, Bernstein M, Buchanan GR, Pollock BH, Camitta BM. Polyethylene glycol-conjugated L-Asparaginase versus native L-Asparaginase in combination with standard agents for children with acute lymphoblastic leukemia in second bone marrow relapse: A Children's Oncology Group Study (POG 8866). J. Pediatr. Hematol. Oncol. 33(8), 610-616 (2011).
31. Abshire TC, Pollock BH, Billett AL, Bradley P, Buchanan GR. Weekly polyethylene glycol conjugated L-Asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: A Pediatric Oncology Group Study. Blood 96(5), 1709-1715 (2000).
32. Stock W, Douer D, Deangelo DJ et al. Prevention and management of asparaginase/ pegasparaginase-Associated toxicities in adults and older adolescents: Recommendations of an expert panel. Leuk. Lymphoma 52(12), 2237-2253 (2011).
33. Hawkins DS, Park JR, Thomson BG et al. Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-Asparaginase therapy for children with relapsed acute lymphoblastic leukemia. Clin. Cancer Res. 10(16), 5335-5341 (2004).
34. Billett AL, Carls A, Gelber RD, Sallan SE. Allergic reactions to Erwinia asparaginase in children with acute lymphoblastic leukemia who had previous allergic reactions to Escherichia coli asparaginase. Cancer 70(1), 201-206 (1992).
35. Moghrabi A, Levy DE, Asselin B et al. Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Blood 109(3), 896-904 (2007).
36. Albertsen BK, Schroder H, Jakobsen P et al. Antibody formation during intravenous and intramuscular therapy with Erwinia asparaginase. Med. Pediatr. Oncol. 38(5), 310-316 (2002).
37. Albertsen BK, Schroder H, Jakobsen P, Muller HJ, Carlsen NT, Schmiegelow K. Monitoring of Erwinia asparaginase therapy in childhood ALL in the Nordic countries. Br. J. Clin. Pharmacol. 52(4), 433-437 (2001).
38. Albertsen BK, Schroder H, Ingerslev J et al. Comparison of intramuscular therapy with Erwinia asparaginase and asparaginase medac: Pharmacokinetics, pharmacodynamics, formation of antibodies and influence on the coagulation system. Br. J. Haematol. 115(4), 983-990 (2001).
39. Wang B, Relling MV, Storm MC et al. Evaluation of immunologic crossreaction of antiasparaginase antibodies in acute lymphoblastic leukemia (ALL) and lymphoma patients. Leukemia 17(8), 1583-1588 (2003).
40. Nesbit M, Chard R, Evans A, Karon M, Hammond GD. Evaluation of intramuscular versus intravenous administration of L-Asparaginase in childhood leukemia. Am. J. Pediatr. Hematol. Oncol. 1(1), 9-13 (1979).
41. Avramis VI, Panosyan EH. Pharmacokinetic/pharmacodynamic relationships of asparaginase formulations: The past, the present and recommendations for the future. Clin. Pharmacokinet. 44(4), 367-393 (2005).
42. Panetta JC, Gajjar A, Hijiya N et al. Comparison of native E. coli and PEG asparaginase pharmacokinetics and pharmacodynamics in pediatric acute lymphoblastic leukemia. Clin. Pharmacol. Ther. 86(6), 651-658 (2009).
43. Cheung NK, Chau IY, Coccia PF. Antibody response to Escherichia coli L-Asparaginase. Prognostic significance and clinical utility of antibody measurement. Am. J. Pediatr. Hematol. Oncol. 8(2), 99-104 (1986).
44. Woo MH, Hak LJ, Storm MC et al. Anti-Asparaginase antibodies following E. coli asparaginase therapy in pediatric acute lymphoblastic leukemia. Leukemia 12(10), 1527-1533 (1998).
45. Douer D, Yampolsky H, Cohen LJ et al. Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia. Blood 109(7), 2744-2750 (2007).
46. Aguayo A, Cortes J, Thomas D, Pierce S, Keating M, Kantarjian H. Combination therapy with methotrexate, vincristine, polyethylene-glycol conjugated-Asparaginase, and prednisone in the treatment of patients with refractory or recurrent acute lymphoblastic leukemia. Cancer 86(7), 1203-1209 (1999).
47. August KJ, Miller WP, Dalton A, Shinnick S. Comparison of hypersensitivity reactions to PEG-Asparaginase in children after intravenous and intramuscular administration. J. Pediatr. Hematol. Oncol. 35(7), e283-286 (2013).
48. Pidaparti M, Bostrom B. Comparison of allergic reactions to pegasparaginase given intravenously versus intramuscularly. Pediatr. Blood Cancer 59(3), 436-439 (2012).
49. Pieters R, Appel I, Kuehnel HJ et al. Pharmacokinetics, pharmacodynamics, efficacy, and safety of a new recombinant asparaginase preparation in children with previously untreated acute lymphoblastic leukemia: A randomized Phase 2 clinical trial. Blood 112(13), 4832-4838 (2008).
50. Albertsen BK, Jakobsen P, Schroder H, Schmiegelow K, Carlsen NT. Pharmacokinetics of Erwinia asparaginase after intravenous and intramuscular administration. Cancer Chemother. Pharmacol. 48(1), 77-82 (2001).
51. Petersen W, Clark D, Senn S, Cash T, Keller F, Lew G. PEGaspargase administration in children with acute lymphoblastic leukemia. Presented at: The Meeting of the American Society of Pediatric Hematology Oncology. Montreal, Canada April 7-10, 2010.
52. Evans WE, Tsiatis A, Rivera G et al. Anaphylactoid reactions to Escherichia coli and Erwinia asparaginase in children with leukemia and lymphoma. Cancer 49(7), 1378-1383 (1982).
53. Asselin BL, Kurtzberg J. Asparaginase In: Asparaginase in Treatment of Acute Leukemias: New Directions for Clinical Research, Pui CH (Ed.). Humana Press, NJ, USA (2003).
54. Chen SH, Pei D, Yang W et al. Genetic variations in GRIA1 on chromosome 5q33 related to asparaginase hypersensitivity. Clin. Pharmacol. Ther. 88(2), 191-196 (2010).
55. Hunger S, COG Pharmacy Committee. Parental and oral chemotherapy administration guidelines used by the Children's Oncology Group (Version 6). Archives of the Children's Oncology Group (2010).
56. Rizzari C, Conter V, Stary J, Colombini A, Moericke A, Schrappe M. Optimizing asparaginase therapy for acute lymphoblastic leukemia. Curr. Opin. Oncol. 25(Suppl. 1), S1-S9 (2013).
57. Amylon MD, Shuster J, Pullen J et al. Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: A Pediatric Oncology Group study. Leukemia 13(3), 335-342 (1999).
58. Riccardi R, Holcenberg JS, Glaubiger DL, Wood JH, Poplack DG. L-Asparaginase pharmacokinetics and asparagine levels in cerebrospinal fluid of rhesus monkeys and humans. Cancer Res. 41(11 Pt 1), 4554-4558 (1981).
59. Erwinaze® [Package Insert]. Eusa Pharma (USA) Inc., PA, USA, March 2014.
60. Wetzler M, Sanford BL, Kurtzberg J et al. Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511. Blood 109(10), 4164-4167 (2007).
61. Pession A, Valsecchi MG, Masera G et al. Long-Term results of a randomized trial on extended use of high dose L-Asparaginase for standard risk childhood acute lymphoblastic leukemia. J. Clin. Oncol. 23(28), 7161-7167 (2005).
62. Asselin BL, Lorenson MY, Whitin JC et al. Measurement of serum L-Asparagine in the presence of L-Asparaginase requires the presence of an L-Asparaginase inhibitor. Cancer Res. 51(24), 6568-6573 (1991).
63. Armstrong JK, Leger R, Wenby RB et al. Occurrence of an antibody to poly(ethylene glycol) in normal donors. Blood 102, 556A (2003).
64. Aibiotech Inc. L-Asparaginase Assay for Leukemia Patients. December 2013.
65. Aibiotech Inc. Laboratory Instructions Manual Assay of Clinical Samples fo L-Asparaginase Levels. December 2013.
66. Covini D, Tardito S, Bussolati O et al. Expanding targets for a metabolic therapy of cancer: L-Asparaginase. Recent Pat. Anticancer Drug Discov. 7(1), 4-13 (2012).